Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company based in Tarrytown, New York, that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in four FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

NASDAQ REGN

$363.41 0.46 (0.13)%

High 366.30 Low 359.97 Volume 586,322 Market Cap 37.63B
01/19/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Jan 13

    Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals in Patent Case Regarding Praluent® (alirocumab) Injection

    Read on
  • Jan 09

    Sanofi and Regeneron Provide Update on Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection

    Read on

EVENTS

  • 35th Annual J.P. Morgan Healthcare Conference
    Jan 9, 2017 | 3:30 PM PT

Events & Presentations

NASDAQ REGN

$363.41 0.46 (0.13)%

High 366.30 Low 359.97 Volume 586,322 Market Cap 37.63B
01/19/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information